Skip to contentC
Cerenome, Inc.
C
CNSYCerenome, Inc. Q2 2025 · 10-Q
Revenue$1.39M$1.39M+8.7% vs Q2 2024 Net Income$5.15M$5.15MN/M vs Q2 2024 EPS Diluted-$0.16-$0.16N/M vs Q2 2024 Operating Income-$1,538,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cerenome, Inc. · CIK 1095981 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$5,805,000N/M Margins · derivedOperating margin-110.6%+178.4 pt vs Q2 2024
Net margin370.6%+600.4 pt vs Q2 2024
ended Jun 30, 2025 · filed Aug 14, 2025 · 45 d after period end